First Trust Nasdaq Pharmaceuticals ETF
FTXH
24 hedge funds and large institutions have $8.12M invested in First Trust Nasdaq Pharmaceuticals ETF in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 0 closing their positions.
26% more funds holding
Funds holding: 19 → 24 (+5)
0.96% more ownership
Funds ownership: 38.77% → 39.73% (+0.96%)
0% less capital invested
Capital invested by funds: $8.13M → $8.12M (-$14K)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$587K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$560K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$521K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$340K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$165K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPIA
Steward Partners Investment Advisory
New York
|
-$1.23M |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$508K |
| 3 |
LPL Financial
San Diego,
California
|
-$229K |
| 4 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
-$57.7K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$29K |
FTXH Hedge Fund Activity: Q2 2024 in Review
24 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2024, worth a combined $8.12M — down 0.17% from $8.13M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FTXH positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $587K. The largest seller was Steward Partners Investment Advisory, cutting an estimated $1.23M.
- 24 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2024, up from 19 in Q1 2024.
- Funds reported $8.12M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2024, down 0.17% quarter-over-quarter.
- 5 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2024 and 0 closed out, a net change of +5 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2024 was Goldman Sachs, an estimated $587K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2024 was Steward Partners Investment Advisory, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2024.